Rapid Antiretroviral Therapy Initiation for HIV Management

Rapid initiation of antiretroviral therapy (ART) following an HIV diagnosis has emerged as a critical strategy to curtail viral replication, reduce morbidity and mortality, and prevent onward transmission. Traditionally, ART commencement involved multiple clinic visits for laboratory assessments and counselling, often leading to delays and loss from the care cascade. The move towards same-day or rapid ART initiation seeks to simplify this process, fostering higher uptake, earlier viral suppression and improved long-term retention in care. Practical applications have spanned diverse settings—from urban clinics in sub-Saharan Africa to community-based testing campaigns—highlighting the role of point-of-care diagnostics, streamlined counselling and integrase inhibitor–based regimens in achieving prompt treatment. This approach aligns with global goals to reach viral suppression targets, optimise individual health outcomes and reduce the public health burden of HIV.

Research from Nature Portfolio

Observational findings demonstrate that initiating ART at the first post-diagnosis visit can lead to exceptionally rapid viral load reduction. In one analysis, newly diagnosed individuals beginning treatment within thirty days achieved a median eight-day interval from regimen offer to initiation. Those on integrase inhibitor–based regimens reached viral suppression in a shorter timeframe than on protease inhibitor–based alternatives, with suppression rates exceeding 80 per cent by week 24 and 88 per cent by week 48. These data underscore the feasibility and efficacy of very early ART initiation in both acute and chronic infection phases when supported by streamlined clinical pathways.

Rapid Antiretroviral Therapy Initiation for HIV Management publication trend

The graph below shows the total number of articles in rapid antiretroviral therapy initiation for hiv management across all publications each year (not limited to Nature Index journals).

Technical terms

Antiretroviral therapy (ART): A combination of medications that suppress HIV replication and prevent disease progression.

Viral suppression: Reduction of HIV RNA in blood to undetectable or very low levels, minimising disease progression and transmission.

Retention in care: Continued engagement of patients in HIV treatment services over time, crucial for sustained viral suppression.

Virological failure: Inability to achieve or maintain viral suppression after ART initiation, often defined by a threshold viral load.

Integrase inhibitor: A class of ART drugs that block the HIV enzyme integrase, preventing viral DNA integration into the host genome.

CD4 cell count: A measure of immune status in people with HIV, indicating the number of CD4-positive T lymphocytes per cubic millimetre of blood.

References

1. Rapid HIV Viral Load Suppression in those Initiating Antiretroviral Therapy at First Visit after HIV Diagnosis. Scientific Reports (2016).
2. Same-day testing with initiation of antiretroviral therapy or tuberculosis treatment versus standard care for persons presenting with tuberculosis symptoms at HIV diagnosis: A randomized open-label trial from Haiti. PLOS Medicine (2023).
3. Long‐term outcomes of rapid antiretroviral NNRTI‐based initiation among Thai youth living with HIV: a national registry database study. Journal of the International AIDS Society (2023).
4. HIV test-and-treat policy improves clinical outcomes in Zambian adults from Southern Province: a multicenter retrospective cohort study. Frontiers in Public Health (2023).